# Hydrochlorothiazide for Kidney Stone Recurrence Prevention

> **NCT03057431** · PHASE3 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 416 (actual)

## Conditions studied

- Nephrolithiasis

## Interventions

- **DRUG:** Placebo oral capsule
- **DRUG:** 12.5 mg hydrochlorothiazide
- **DRUG:** 25.0 mg hydrochlorothiazide
- **DRUG:** 50.0 mg hydrochlorothiazide

## Key facts

- **NCT ID:** NCT03057431
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2021-12-03
- **Final completion:** 2022-04-30
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057431, "Hydrochlorothiazide for Kidney Stone Recurrence Prevention". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03057431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*